Clinical Use of Markers of Neurohormonal Activation in Heart Failure
نویسنده
چکیده
Rev Esp Cardiol 2004;57(4):347-56 347 Chronic heart failure secondary to ventricular dysfunction is characterized by neurohormonal activation, reflected mainly as increased sympathetic and reninangiotensin system activation. Increased plasma levels of several neurohormones have been associated with increased morbidity and mortality. Neurohormone activation is part of the mechanism of compensation that is activated to maintain hemodynamic stability when heart output is reduced. Despite the initial benefits of this mechanism, neurohormone activation has been shown to contribute to progressive impairment of ventricular function and symptoms of heart failure, such that the greater the degree of activation, the worse the prognosis. Despite their important implications for prognosis, plasma neurohormone levels are not measured in clinical practice as part of the clinical evaluation of patients with heart failure. Medical treatment with ACE inhibitors and beta blockers, by lowering the plasma levels of some neurohormones, reduces their prognostic usefulness in establishing risk. Thus, no ideal biomarker is yet available that is stable and easy to measure, and that accurately established risk in patients with heart failure. Such a marker should also have an acceptable cost/benefit ratio.
منابع مشابه
[Clinical use of markers of neurohormonal activation in heart failure].
Chronic heart failure secondary to ventricular dysfunction is characterized by neurohormonal activation, reflected mainly as increased sympathetic and renin-angiotensin system activation. Increased plasma levels of several neurohormones have been associated with increased morbidity and mortality. Neurohormone activation is part of the mechanism of compensation that is activated to maintain hemo...
متن کاملAuthor's response to reviews Title: Body Mass Index in Chronic Heart Failure: Association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction Authors:
متن کامل
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease.
Although heart failure has been viewed primarily as a haemodynamic disorder, the development of pharmacologic agents that address the haemodynamic derangements has not proved to be a successful approach to its management. Consequently, attention in recent years has shifted to the development of neurohormonal antagonists in the hope that prolonged interference with the renin-angiotensin system a...
متن کاملSystems Biology and Biomechanical Model of Heart Failure
Heart failure is seen as a complex disease caused by a combination of a mechanical disorder, cardiac remodeling and neurohormonal activation. To define heart failure the systems biology approach integrates genes and molecules, interprets the relationship of the molecular networks with modular functional units, and explains the interaction between mechanical dysfunction and cardiac remodeling. T...
متن کاملNeurohormonal Hypothesis in Heart Failure
A ccording to the neurohormonal model, heart failure is a syndrome that develops because an initial heart injury activates endogenous neurohormonal systems that exert a deleterious effect to the myocardium and on the circulation. This new model regards heart failure primarily as a neurohormonal disorder with main pathophysiologic abnormality the activation of various neurohormonal systems. Arte...
متن کامل